Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multicenter pharmacological observational prospective, no-profit, study.
This study was designed to get a "real-life" snapshot across several Italian Hepatology centers. All HDV patients are followed up according to EASL 2017 guidelines. This allows uniformity on the indication for antiviral treatment and management of that antiviral therapy. No off-label medications are used. All data are retrievable from the patient's medical record. In addition, clinical and biochemical data from patients at month 0, 1, 2, 4, 6 and 12 of treatment, and otherwise within the study period, will be collected longitudinally.
The primary objective of the study is to describe the virological response to BLV in all patients starting BLV therapy for CHD, defined as a >2 Log decline in HDV-RNA or undetectable HDV-RNA (using the Robogene 2.0 quantitative kit, LLQ <6 IU/ml) at month 12 of therapy.
HDV patients who will start therapy with BLV 2 mg/day from May 2023, according to AIFA guidelines, will be consecutively enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hepatis Delta | Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bulevirtide | Drug | dose of 2 mg/day subcutaneously |
|
| Measure | Description | Time Frame |
|---|---|---|
| Describe the virological response to BLV in all patients starting BLV therapy for CHD | Percentage of patients with undetectable HDV RNA | Month 6 |
| Describe the virological response to BLV in all patients starting BLV therapy for CHD | Percentage of patients with ≥ 2 log IU/ml decline of HDV RNA | Month 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Month 6 |
| Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients with CHD (quantifiable HDV-RNA) who will start treatment with BLV 2 mg/day during the study period at the S.C. Gastroenterology and Hepatology (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) and at participating centers, and who met the inclusion criteria and none of the exclusion criteria.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy. | Recruiting | Milan | MI | 20122 | Italy |
Not provided
| ID | Term |
|---|---|
| D003699 | Hepatitis D |
| ID | Term |
|---|---|
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718249 | bulevirtide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA |
| Month 12 |
| Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Proportion of patients with virological response, defined as undetectable HDV-RNA | Month 6 |
| Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Proportion of patients with virological response, defined as undetectable HDV-RNA | Month 12 |
| Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 6 |
| Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 12 |
| Evaluation of the percentage of patients with normal ALT | Percentage of patients with normal ALT | Month 6 |
| Evaluation of the percentage of patients with normal ALT | Percentage of patients with normal ALT | Month 12 |
| Evaluation of the percentage of patients with clinical response, i.e., the percentage of patients who remain free of liver complications, such as HCC or decompensation | Percentage of patients who remain free of liver complications (de novo HCC or onset of decompensation) | Month 6 |
| Evaluation of the percentage of patients with clinical response, i.e., the percentage of patients who remain free of liver complications, such as HCC or decompensation | Percentage of patients who remain free of liver complications (de novo HCC or onset of decompensation) | Month 12 |
| Investigation of changes over time in serum levels of HBsAg (UI/mL) | Change in serum levels of HBsAg- by medians and ranges | Month 6 |
| Investigation of changes over time in serum levels of HBsAg (UI/mL) | Change in serum levels of HBsAg- by medians and ranges | Month 12 |
| Investigation of changes over time in serum levels of albumin (g/dL) | Change in serum levels albumin- by medians and ranges | Month 6 |
| Investigation of changes over time in serum levels of albumin (g/dL) | Change in serum levels albumin- by medians and ranges | Month 12 |
| Investigation of changes over time in serum levels of platelets (10e9/L) | Change in serum levels of platelets - by medians and ranges | Month 6 |
| Investigation of changes over time in serum levels of platelets (10e9/L) | Change in serum levels of platelets - by medians and ranges | Month 12 |
| Investigation of changes over time in serum levels of AFP (µg/L) | Change in serum levels of AFP - by medians and ranges | Month 6 |
| Investigation of changes over time in serum levels of AFP (µg/L) | Change in serum levels of AFP - by medians and ranges | Month 12 |
| Evaluation of treatment safety | Occurrence of change in serum bile acid levels (µmol/L) | Month 6 |
| Evaluation of treatment safety | Occurrence of adverse events | Month 6 |
| Evaluation of treatment safety | Occurrence of change in serum bile acid levels (µmol/L) | Month 12 |
| Evaluation of treatment safety | Occurrence of adverse events | Month 12 |
| D006505 |
| Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |